Aanjaay Industries
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Kabra Drugs has received a Letter of Intent from the Government of Chhattisgarh for a proposed ₹200 crore investment to establish a pharmaceutical manufacturing facility at Nava Raipur Pharma Park. The project, announced after a connect at the Hyderabad Investors Connect, is expected to generate approximately 250 direct and indirect jobs. The company plans to use the facility to expand its manufacturing capabilities and support long-term growth. The proposed investment is subject to execution of definitive agreements and receipt of necessary approvals and incentives from the state government. The LOI marks a significant step in the company's strategic diversification into large-scale pharmaceutical manufacturing.
Powered by Tijori
Kabra Drugs has received a Letter of Intent from the Government of Chhattisgarh for a proposed ₹200 crore investment to establish a pharmaceutical manufacturing facility at Nava Raipur Pharma Park. The project, announced after a connect at the Hyderabad Investors Connect, is expected to generate approximately 250 direct and indirect jobs. The company plans to use the facility to expand its manufacturing capabilities and support long-term growth. The proposed investment is subject to execution of definitive agreements and receipt of necessary approvals and incentives from the state government. The LOI marks a significant step in the company's strategic diversification into large-scale pharmaceutical manufacturing.
Powered by Tijori
May 6 (Reuters) - Kabra Drugs Ltd KABD.BO:
KABRA DRUGS LTD - APPROVES EXPANSION OF PHARMACEUTICAL MANUFACTURING AND MARKETING BUSINESS
Source text: ID:nBSE9jJpzQ
Further company coverage: KABD.BO
(([email protected];))
May 6 (Reuters) - Kabra Drugs Ltd KABD.BO:
KABRA DRUGS LTD - APPROVES EXPANSION OF PHARMACEUTICAL MANUFACTURING AND MARKETING BUSINESS
Source text: ID:nBSE9jJpzQ
Further company coverage: KABD.BO
(([email protected];))
Jan 1 (Reuters) - Kabra Drugs Ltd KABD.BO:
APPROVAL FOR ACQUISITION OF VASSMAAN AUTOMATIVE
AGREEMENT TO APPOINT 200 CHANNEL PARTNERS NATIONWIDE
Source text: ID:nBSEb21dPZ
Further company coverage: KABD.BO
(([email protected];))
Jan 1 (Reuters) - Kabra Drugs Ltd KABD.BO:
APPROVAL FOR ACQUISITION OF VASSMAAN AUTOMATIVE
AGREEMENT TO APPOINT 200 CHANNEL PARTNERS NATIONWIDE
Source text: ID:nBSEb21dPZ
Further company coverage: KABD.BO
(([email protected];))
June 18 (Reuters) - Kabra Drugs Ltd KABD.BO:
RECEIVES FDA PERMISSION TO MANUFACTURE AND SELL FROM CHENNAI FACILITY
TO ESTABLISH SUBSIDIARY FOR AI AND MACHINE LEARNING IN PHARMA
BOARD REQUESTS STRATEGY FOR ACQUISITION OF BONN SCHTERING BIO SCIENCES
APPROVES ACQUISITION OF AMR PHARMA INDIA
AUTHORIZED N. ARAVIND TO APPOINT CHANNEL PARTNERS TO SELL OWN BRAND OF MEDICINES
Source text: ID:nBSE7RzvPc
Further company coverage: KABD.BO
(([email protected];;))
June 18 (Reuters) - Kabra Drugs Ltd KABD.BO:
RECEIVES FDA PERMISSION TO MANUFACTURE AND SELL FROM CHENNAI FACILITY
TO ESTABLISH SUBSIDIARY FOR AI AND MACHINE LEARNING IN PHARMA
BOARD REQUESTS STRATEGY FOR ACQUISITION OF BONN SCHTERING BIO SCIENCES
APPROVES ACQUISITION OF AMR PHARMA INDIA
AUTHORIZED N. ARAVIND TO APPOINT CHANNEL PARTNERS TO SELL OWN BRAND OF MEDICINES
Source text: ID:nBSE7RzvPc
Further company coverage: KABD.BO
(([email protected];;))
Dec 4 (Reuters) - Kabra Drugs Ltd KABD.BO:
KABRA DRUGS - APPROVES RAISING OF FUNDS VIA ISSUE OF SHARES WORTH UPTO 422.6 MILLION RUPEES
KABRA DRUGS - ISSUE OF SHARES ON PREFERENTIAL ALLOTMENT BASIS
Further company coverage: KABD.BO
(([email protected];))
Dec 4 (Reuters) - Kabra Drugs Ltd KABD.BO:
KABRA DRUGS - APPROVES RAISING OF FUNDS VIA ISSUE OF SHARES WORTH UPTO 422.6 MILLION RUPEES
KABRA DRUGS - ISSUE OF SHARES ON PREFERENTIAL ALLOTMENT BASIS
Further company coverage: KABD.BO
(([email protected];))
Nov 4 (Reuters) - Kabra Drugs Ltd KABD.BO:
APPROVES RAISING OF FUNDS FOR AN ISSUE UP TO 20 MILLION SHARES
Source text: ID:nBSE8jDGYm
Further company coverage: KABD.BO
(([email protected];;))
Nov 4 (Reuters) - Kabra Drugs Ltd KABD.BO:
APPROVES RAISING OF FUNDS FOR AN ISSUE UP TO 20 MILLION SHARES
Source text: ID:nBSE8jDGYm
Further company coverage: KABD.BO
(([email protected];;))
Oct 21 (Reuters) - Kabra Drugs Ltd KABD.BO:
KABRA DRUGS LTD - TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nBSE13Sh4t
Further company coverage: KABD.BO
(([email protected];))
Oct 21 (Reuters) - Kabra Drugs Ltd KABD.BO:
KABRA DRUGS LTD - TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nBSE13Sh4t
Further company coverage: KABD.BO
(([email protected];))
Jan 18 (Reuters) - Kabra Drugs Ltd KABD.BO:
TO CONSIDER AND APPROVE PROPOSAL OF FUND RAISING
Further company coverage: KABD.BO
(([email protected];))
Jan 18 (Reuters) - Kabra Drugs Ltd KABD.BO:
TO CONSIDER AND APPROVE PROPOSAL OF FUND RAISING
Further company coverage: KABD.BO
(([email protected];))
Dec 8 (Reuters) - Kabra Drugs Ltd KABD.BO:
TO DISCUSS ABOUT EXPANSION AND BRINING IN NEW BUSINESS
Source text for Eikon: ID:nBSE7tFZ75
Further company coverage: KABD.BO
(([email protected];))
Dec 8 (Reuters) - Kabra Drugs Ltd KABD.BO:
TO DISCUSS ABOUT EXPANSION AND BRINING IN NEW BUSINESS
Source text for Eikon: ID:nBSE7tFZ75
Further company coverage: KABD.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Aanjaay Industries do?
Founded in 1989, Kabra Drugs Ltd is a pharmaceutical company based in Indore, Madhya Pradesh. They specialize in manufacturing injectables, liquids, soft gel caps, solvents, and anaesthetics under Segment A.
Who are the competitors of Aanjaay Industries?
Aanjaay Industries major competitors are Vivo Bio Tech, Bacil Pharma, Biofil Chem & Pharma, Vista Pharmaceutical, Mangalam Drugs&Org., Vivimed Labs, Shelter Pharma. Market Cap of Aanjaay Industries is ₹51 Crs. While the median market cap of its peers are ₹46 Crs.
Is Aanjaay Industries financially stable compared to its competitors?
Aanjaay Industries seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Aanjaay Industries pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Aanjaay Industries latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Aanjaay Industries allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Aanjaay Industries balance sheet?
Balance sheet of Aanjaay Industries is moderately strong.
Is the profitablity of Aanjaay Industries improving?
The profit is oscillating. The profit of Aanjaay Industries is ₹4.97 Crs for TTM, -₹1.09 Crs for Mar 2025 and -₹0.74 Crs for Mar 2024.
Is the debt of Aanjaay Industries increasing or decreasing?
Yes, The net debt of Aanjaay Industries is increasing. Latest net debt of Aanjaay Industries is -₹10.15 Crs as of Mar-26. This is greater than Mar-25 when it was -₹42.04 Crs.
Is Aanjaay Industries stock expensive?
Aanjaay Industries is not expensive. Latest PE of Aanjaay Industries is 10.38, while 3 year average PE is 13.01. Also latest EV/EBITDA of Aanjaay Industries is 7.71 while 3yr average is 7.92.
Has the share price of Aanjaay Industries grown faster than its competition?
Aanjaay Industries has given better returns compared to its competitors. Aanjaay Industries has grown at ~75.11% over the last 2yrs while peers have grown at a median rate of -27.04%
Is the promoter bullish about Aanjaay Industries?
There is Insufficient data to gauge this.
Are mutual funds buying/selling Aanjaay Industries?
There is Insufficient data to gauge this.